Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
NCT ID: NCT00169559
Last Updated: 2012-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
250 participants
INTERVENTIONAL
2003-11-30
2005-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Placebo
GW590735
1µg to 20µg daily doses of GW590735
fenofibrate
Marketed Drug
Arm 2
Fenofibrate
GW590735
1µg to 20µg daily doses of GW590735
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GW590735
1µg to 20µg daily doses of GW590735
fenofibrate
Marketed Drug
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Triglycerides greater than or equal to 120 mg/dL and less than or equal to 500 mg/dL.
* Women must be surgically sterile or postmenopausal.
Exclusion Criteria
* Diabetes
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Scottsdale, Arizona, United States
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
Healdsburg, California, United States
GSK Investigational Site
Orange, California, United States
GSK Investigational Site
Spring Valley, California, United States
GSK Investigational Site
Walnut Creek, California, United States
GSK Investigational Site
DeLand, Florida, United States
GSK Investigational Site
Fort Lauderale, Florida, United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Hollywood, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Pembroke Pines, Florida, United States
GSK Investigational Site
Orland Park, Illinois, United States
GSK Investigational Site
Evansville, Indiana, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
Iowa City, Iowa, United States
GSK Investigational Site
Louisville, Kentucky, United States
GSK Investigational Site
Auburn, Maine, United States
GSK Investigational Site
Brooklyn Center, Minnesota, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Endwell, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Rochester, New York, United States
GSK Investigational Site
Williamsville, New York, United States
GSK Investigational Site
Statesville, North Carolina, United States
GSK Investigational Site
Wilmington, North Carolina, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Medford, Oregon, United States
GSK Investigational Site
Allentown, Pennsylvania, United States
GSK Investigational Site
Erie, Pennsylvania, United States
GSK Investigational Site
Sioux Falls, South Dakota, United States
GSK Investigational Site
Bristol, Tennessee, United States
GSK Investigational Site
Kingsport, Tennessee, United States
GSK Investigational Site
Bryan, Texas, United States
GSK Investigational Site
Conroe, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Norfolk, Virginia, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Laval, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Sainte-Foy, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PAA20001
Identifier Type: -
Identifier Source: org_study_id